Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C25H24FN5O3 |
| Molecular Weight | 461.4882 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CCCCC1=CC(=CC(=O)N1CC2=C(F)C=C(C=C2)C3=C(C=CC=C3)C4=NN=NN4)C(=O)OC
InChI
InChIKey=LYVGOAYMIAQLHI-UHFFFAOYSA-N
InChI=1S/C25H24FN5O3/c1-3-4-7-19-12-18(25(33)34-2)14-23(32)31(19)15-17-11-10-16(13-22(17)26)20-8-5-6-9-21(20)24-27-29-30-28-24/h5-6,8-14H,3-4,7,15H2,1-2H3,(H,27,28,29,30)
Embusartan or BAY106734 (6-n-butyl-4-methoxycarbonyl-2-oxo-1[(2'-(1H-tetrazol-5-yl) -3-fluorobiphenyl-4-yl)methyl] 1,2-dihydropyridine) is an angiotensin II receptors antagonist. Embusartan has beneficial effects in different animal hypertension models. Embusartan appears as a potent and specific new inhibitor of angiotensin II-induced growth-related events in vascular smooth muscle cells. It was being developed for the treatment of hypertension.
Originator
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| Long-term blockade of the angiotensin II receptor in renin transgenic rats, salt-loaded Dahl rats, and stroke-prone spontaneously hypertensive rats. | 1997 Sep |
|
| Effects of BAY 10-6734 (Embusartan), a new angiotensin II type I receptor antagonist, on vascular smooth muscle cell growth. | 1999 Apr |
|
| AT(1) receptor blockers prevent sympathetic hyperactivity and hypertension by chronic ouabain and hypertonic saline. | 2001 Mar |
Patents
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C66930
Created by
admin on Fri Dec 15 15:35:45 GMT 2023 , Edited by admin on Fri Dec 15 15:35:45 GMT 2023
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
CHEMBL1742441
Created by
admin on Fri Dec 15 15:35:45 GMT 2023 , Edited by admin on Fri Dec 15 15:35:45 GMT 2023
|
PRIMARY | |||
|
133000
Created by
admin on Fri Dec 15 15:35:45 GMT 2023 , Edited by admin on Fri Dec 15 15:35:45 GMT 2023
|
PRIMARY | |||
|
DTXSID50166029
Created by
admin on Fri Dec 15 15:35:45 GMT 2023 , Edited by admin on Fri Dec 15 15:35:45 GMT 2023
|
PRIMARY | |||
|
C81521
Created by
admin on Fri Dec 15 15:35:45 GMT 2023 , Edited by admin on Fri Dec 15 15:35:45 GMT 2023
|
PRIMARY | |||
|
C109119
Created by
admin on Fri Dec 15 15:35:45 GMT 2023 , Edited by admin on Fri Dec 15 15:35:45 GMT 2023
|
PRIMARY | |||
|
156001-18-2
Created by
admin on Fri Dec 15 15:35:45 GMT 2023 , Edited by admin on Fri Dec 15 15:35:45 GMT 2023
|
PRIMARY | |||
|
100000080754
Created by
admin on Fri Dec 15 15:35:45 GMT 2023 , Edited by admin on Fri Dec 15 15:35:45 GMT 2023
|
PRIMARY | |||
|
SUB06501MIG
Created by
admin on Fri Dec 15 15:35:45 GMT 2023 , Edited by admin on Fri Dec 15 15:35:45 GMT 2023
|
PRIMARY | |||
|
7527
Created by
admin on Fri Dec 15 15:35:45 GMT 2023 , Edited by admin on Fri Dec 15 15:35:45 GMT 2023
|
PRIMARY | |||
|
4MY73645XA
Created by
admin on Fri Dec 15 15:35:45 GMT 2023 , Edited by admin on Fri Dec 15 15:35:45 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
